{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"Antiplatelets After ASCVD: Less Autopilot, More Judgment \ud83e\udded","description":"\ud83e\ude78 Antiplatelet therapy is no longer \u201caspirin for all\u201d or \u201cDAPT by habit.\u201d The 2026 ACC Scientific Statement reframes care around precision: ischemic risk, bleeding risk, PCI\/ACS context, PAD or stroke phenotype, surgery, anticoagulation, and adherence. The modern message: choose the right agent, right intensity, and right duration\u2014then reassess. Platelets may be small, but the decisions are not. \u2696\ufe0f\ud83d\udd2c Source: 2026 ACC Scientific Statement on antiplatelet therapy. ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41947025\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/203721670"}